Artificial Expression Constructs for Claustrum Neuron Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for labeling and perturbing specific cell types in the brain, such as those using recombinase driver lines, are costly and require germline transgenic animals, making them unsuitable for human applications and inefficient due to low frequency of experimental animals and the need for triple transgenic crosses.
Innovation Solution
Development of artificial expression constructs that utilize specific enhancers like MGT_E51, MGT_E52, MGT_E57, eHGT_770m, eHGT_774m, eHGT_772m, eHGT_486m, eHGT_875m, eHGT_923m, eHGT_924m, eHGT_925m, and eHGT_926m to drive gene expression in claustrum neurons, providing higher levels and faster onset of transgene expression, and are applicable in both mouse and human models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If recombinase driver lines are used to label cell populations, then cell type labeling is achieved, but the process becomes costly and requires germline transgenic animals with triple transgenic crosses yielding low frequency of experimental animals
Solution Approach 1:
The invention segments the gene expression control into modular components: tissue-specific promoters (e.g., HTR2A promoter for claustrum neurons), enhancer elements, and reporter genes. This modular construction allows independent optimization of each component, achieving high cell-type specificity without requiring complex triple transgenic crosses. The segmented approach enables simpler breeding schemes and higher experimental animal frequency while maintaining precise cell labeling.
Solution Approach 2:
The invention creates universal expression constructs that can be applied across multiple cell types and species by using commonly available promoters and enhancers. The standardized construct design with interchangeable promoter-enhancer-reporter modules provides a universal platform for cell type-specific expression, eliminating the need for custom germline transgenic lines for each new cell type of interest.
2Measurement precision
If recombinase driver lines are used for cell labeling, then cell type definition is achieved, but the creation and maintenance of such lines is costly and time-consuming
Solution Approach 1:
The invention performs preliminary action by pre-characterizing and validating promoter-enhancer combinations for specific cell type specificity before application. The HTR2A promoter and associated enhancers have been预先 validated to drive expression specifically in claustrum neurons. This preliminary validation eliminates the need for time-consuming creation and maintenance of custom transgenic lines for each new experiment, as researchers can directly use the pre-validated constructs.
Solution Approach 2:
The invention uses copying by replicating the validated promoter-enhancer-reporter construct design across different experimental contexts. Once a construct is validated for a specific cell type (e.g., claustrum neurons using HTR2A promoter), the same modular construct can be copied and applied to study other aspects of that cell type's function without requiring new transgenic line development, significantly reducing time and cost.
3Measurement precision
If germline transgenic animals are used, then cell type-specific expression is achieved, but the approach is not applicable to human studies
Solution Approach 1:
The invention creates universal expression constructs that function across species by using evolutionarily conserved promoter and enhancer elements. The HTR2A promoter and associated regulatory elements show cross-species conservation, allowing the same construct design to drive cell-type-specific expression in both mouse and human neurons. This universality enables translation of findings from animal models to human studies without requiring species-specific construct development.
Solution Approach 2:
The invention applies parameter changes by optimizing promoter and enhancer sequences for cross-species functionality. The constructs use conserved regulatory sequences and codon-optimized coding regions that maintain function across mammalian species. This parameter optimization allows the same expression construct to achieve cell-type-specific expression in both mouse and human systems, bridging the gap between preclinical and clinical research.
Data Source
AI summary
Artificial expression constructs for modulating gene expression in targeted central nervous system cell types are described. The artificial expression constructs can be used to express synthetic genes or modify gene expression in claustrum neurons including L6 IT Car3 neurons.